Introduction Initiation of class III anti-arrhythmic medications requires telemetric monitoring for ventricular arrhythmias and QT prolongation to reduce the risk of torsades de pointes (TdP). Heart rate-corrected QT interval (QTc) is an indicator of risk, however it is imperfect, and subtle abnormalities of repolarization have been linked with arrhythmogenesis. Purpose Identification of electrocardiographic predictors of torsadogenic risk through the application of a novel T wave analysis tool. Methods Among all patients admitted to Mayo Clinic for initiation of dofetilide or sotalol, we identified 13 cases who developed drug-induced TdP and 26 age and sex matched controls that did not develop TdP. The immediate pre-TdP ECG of those with TdP was compared to the last ECG performed prior to hospital discharge in controls using a novel T wave program that quantified subtle changes in T wave morphology.
Introduction
Sotalol and dofetilide (Class III anti-arrhythmic drugs [AADs] ) are used commonly to maintain sinus rhythm in patients with atrial fibrillation [1] . Initiation of these medications requires serial 12-lead ECGs with QTc measurement until a steady-state drug level is achieved in order to reduce the risk of torsades de pointes (TdP), a potentially fatal side effect of these medications [2] . The risk of TdP with sotalol and dofetilide is 1-4 % [3] [4] [5] and 2-3 % [6, 7] , respectively.
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The QTc is a well-established indicator of TdP risk but it does not fully account for all risk [2, 8, 9] . T wave changes are described in patients taking Class III agents [10, 11] , but the relationship between individual T wave abnormalities and torsadogenic risk is unknown. The T wave arises due to differential repolarization characteristics of endocardial, midmyocardial and epicardial myocytes. While QTc provides useful information, it reduces to a single measurement complex three dimensional myocardial electrophysiological voltage gradients that change in response to a drug. We hypothesize that novel digital signal processingbased T wave morphologic analysis of the surface ECG may provide insight into subtle changes in T waves that may be linked to arrhythmogenesis [12] [13] [14] . The aim of this project was to improve risk stratification of patients loaded with sotalol and dofetilide by identifying novel electrocardiographic predictors of TdP.
Methods

Study Population
We performed a retrospective analysis of patients admitted to the Mayo Clinic in Rochester, MN, for initiation of dofetilide and sotalol from 1st January 2004-1st January 2014. Cases were identified by a keyword search of the electronic medical record using a query-building tool (Data Discovery and Query Builder). The following keywords were combined with Bsotalol^and Bdofetilide^; Btorsade de pointes^, Btorsade de pointe^, Btorsade^, Btorsades^, Bpolymorphic ventricular tachycardia^, and Bpolymorphic VT^. Patients were included if they met all of the following criteria: 1) admitted for initiation of either sotalol or dofetilide as their AAD, 2) serial ECGs performed, 3) documentation of TdP. Patients were excluded if the ECG had a paced rhythm, if the drug was stopped due to excessive QT prolongation, or patients were taking the drug chronically. Age-and sex-matched controls were identified in a 2:1 ratio from a population of patients who received sotalol or dofetilide loading but did not develop TdP. Echocardiogram data closest to admission date was collected. The Mayo Clinic Institutional Review Board approved this study.
Electrocardiographic Analysis
All ECGs obtained during the admission for AAD loading were selected and analyzed. The ECG recorded closest to the TdP event among the cases was selected for the primary analysis. For the controls (i.e. AAD loaded but without TdP), the ECG before discharge (at steady state of the maximum tolerated dose) was compared with pre-TdP ECG in the cases. The ECG analysis was performed using software that we developed specifically for this study (detailed below). The following ECG features were analyzed:
T-wave left/right slope, T-wave amplitude, T-wave enclosed area, x/y coordinates of the center of gravity (COG) of the first 25 % of a T-wave (T1), x/y coordinates of COG of the last 25 % of a T-wave (T4), QT interval, QTc value (Bazett's heart rate corrected) and Tpeak-Tend (Tpe) interval.
Software Development
We developed a software package in MATLAB (version 2013b, Mathworks Inc. Natick, MA) to facilitate the T-wave analysis. The software provides automatic 12-lead ECG feature extraction followed by an intuitive and interactive way to analyze the T-wave properties of short-term 12-lead ECG data sets measured under current clinical conditions. The block diagram of the workflow is shown in Figure 1 (supplementary file).
The raw, 12-lead ECG tracings (10 s duration, fs=500 samples/s) collected from the General Electric MUSE ECG management system (GE Healthcare, Waukesha, WI) were uploaded into our software tool [15] . Pre-processing procedures are applied including de-noising and baseline correction, both based on wavelet transformations described by Clifford et al. [16] . Pre-processing is followed by ECG feature extraction using our software program. ECG features (mentioned above) from the ECG are detected by a Bayesian statistical peak delineation algorithm [17] . The COGx is calculated by a polygonal method (Figure 2 -supplemental file). Detected T-waves with inconsistent locations (outliers) compared to other cardiac cycles were excluded manually from the analysis (Figure 3 -supplemental file, shows an example of such manual adjustments). When all the outliers are removed, ECG features are calculated and exported to CSV file for statistical analysis.
Statistical Analysis
A univariate two-sample t-test was used to pre-select features that showed statistically significantly different means by case status. Features whose mean significantly (p<0.05) differed between cases and controls underwent further analysis. In order to select independent features, Pearson's correlation coefficient was used to examine correlation between pre-selected features. A filter approach was used to find the features with highest correlation with case status (i.e. dofetilide/sotalolinduced TdP) while having low mutual correlation between features. A mutual correlation threshold of features was chosen to be |ρ<0.6|. Multivariable analysis was performed on the features selected via the filter approach. Simultaneously, an advanced method for feature selection using linear discriminant analysis (LDA) as a wrapper was used in order to compare results with the previous method. The LDA method calls a Forward Sequential Feature Selection (FSFS) in a wrapper fashion. The performance of LDA was tested using 10×10 fold cross-validation. To evaluate and compare performance of features selected by the filter approach and FSFS a 10×10 fold cross-validation using the LDA classifier was also used for features selected by filter approach.
Results
Patient Characteristics
Thirty-nine dofetilide/sotalol-loaded patients (13 cases, 26 controls) underwent advanced T wave analysis for assessment of TdP predictive markers. There were no statistically significant baseline differences observed between cases and controls (Table 1 ). This cohort was predominantly female (75 % in the sotalol group and 80 % in the dofetilide group), and had an average age of 60.3±14.5 years (sotalol group) and 68.0± 5.5 years (dofetilide group). All patients had sinus rhythm documented on the ECG preceding TdP. Twenty-six patients (66.7 %) received either sotalol or dofetilide for atrial fibrillation, 7 (17.9 %) for atrial flutter, 4 (10.2 %) for ventricular ectopy and 2 (5.1 %) for ventricular tachycardia. The mean dose received before the event was 95±19 mg in the sotalol group and 375±158 mg in the dofetilide group. No patient had a previous history of TdP. Average duration before TdP occurred was 3.2 days (±1.8). The average time from analyzed ECG to occurrence of Tdp was 160 min (range, 9-568). Mean ejection fraction was 43.1 % (±18.2) in the sotalol group that experienced TdP and 48 % (±14.5) in dofetilide.
T Wave Characteristics
Significant differences in T wave repolarization were observed across 13 study variables (Table 1 -Supplemental  file) . QTc, QT, COG x-axis (COGx) and COGxT4 were the only variables that had differences observed in all 12 ECGs leads (except Lead I QTc). The QTc and QT interval were longer and the COGx larger (further) on the xaxis in those that experienced TdP compared to controls. 
Discussion
Using our newly developed T wave analysis tool, we found electrocardiographic markers of TdP risk in patients being loaded with sotalol or dofetilide. Several T wave indices significantly differ from controls. Specifically, the QTc in Lead V3 and the right slope of the T wave in Lead I were most strongly correlated with TdP, and, together, could discriminate the majority of TdP cases from controls (classification error 12 %). These indices have the potential to augment current risk stratification, which is based primarily on serial QTc measurements. Sotalol and dofetilide prolong repolarization through inhibition of KCNH2-encoded Kv11.1 (HERG) channels (I Kr currents) and confer an increased risk of drug-induced-TdP. Although the degree of QT prolongation is an imperfect surrogate for torsadogenic potential [15, [18] [19] [20] (the risk of TdP is neither a linear function of the baseline QT interval nor of the extent of QT-interval prolongation during drug administration) [9] , it is important to note that the QTc strongly correlated with TdP events in our cohort. In general, a QTc>500 ms is associated with a higher risk of lethal arrhythmias [21] [22] [23] , and a QTc>500 ms 2 h after dosing is an indication to stop or reduce the dose of sotalol or dofetilide. However, 8/13 (61.5 %) of the TdP cohort did not have a QTc> 500 msec on the ECG preceding TdP. Thus, this 500 msec QTc threshold may not completely identify those at risk. The average QTc in our cohort across all leads in the ECG preceding TdP was 480 msec (most patients were female, in whom the guideline definition of a prolonged QTc is 460 ms). This supports the hypothesis that although the QTc is a partial surrogate marker (able to successfully distinguish torsadogenic cases vs non-torsadogenic controls in 79 %), there is a need for additional risk factor identification. The T wave right slope in Lead I is a novel marker for sotalol/dofetilide induced-TdP. In our cohort, T wave right slope in Lead I correlated highly with arrhythmia risk and provided an additive effect in discriminating cases from controls. The additive ability of T wave right slope lays in its ability to out rule individuals at risk of Tdp due to its high sensitivity and negative predictive value. This slope is essentially a function of the amplitude of the T wave as well as the duration of the terminal portion of the wave. The TdP patients in the cohort had shallow or 'less steep' right slopes compared to their age and sex matched controls (r=0.45). Figure 4a and b provide a visual representation of this shallow T wave. The shallow T wave may reflect greater dispersion of refractoriness in both the repolarisation of the transmural gradients (endocardial, midmyocardial, and epicardial cells) with a contributory role-played by apicobasal gradient. With regard to the components that make up the slope of the T wave, we did observe a nonsignificant trend towards lower T wave amplitudes in those who experienced TdP. Reduction in T wave amplitude has been well described with sotalol administration [10, 24, 25] , and also reported in congenital LQT2 patients [26] [27] [28] (who have I Kr loss-of-function), but we are the first to propose its potential to predict arrhythmia risk. The reason for the reduction in the T wave has yet to be defined. Bhuiyan et al. [29] suggested that flattening of the T wave is a reflection of prolongation of action potential triangulation. Triangulation is defined by the time between 30 % repolarization and 90 % repolarization of the monophasic action potential. A study using the HERG blocker Sertindole showed that the T wave attained minimum height just before the onset of TdP [30] . A shallow right T slope would also suggest that there is prolonged repolarization of the end of the T wave. The Tpe interval is considered a good marker for arrhythmogenic risk [31, 32] . Prolongation of this interval increases the period when potential fatal re-entry ventricular tachycardias can occur and has been shown to be associated with increased risk of mortality and ventricular arrhythmias in long QT syndromes [33] , hypertrophic cardiomyopathy [34] , patients receiving primary percutaneous coronary intervention for an MI [35] , and Brugada syndrome [31] . Here, however, Tpe failed to distinguish cases from controls (Table 1 - supplementary file) . While it is unclear why the T wave right slope proved superior to Tpe, one possibility may be that the end of the T wave can be difficult to define consistently, particularly in the setting of antiarrhythmic drugs, and the slope determination may be more robust in this regard.
It is important to note that there were no differences in QTc and T wave right slope at baseline between cases and controls.
This would suggest that the risk of Tdp is due to individual response in the setting of class III AADs rather than baseline electrical substrate abnormalities. Figure 5 -Supplementary file highlights this nicely as it shows some subtle differences that exist between cases and controls in the analysis of serial ECGs. The top two graphs show the QTc over time. In those that experienced TdP, the average tracing shows an initially gradual, logarithmic increase in QTc towards TdP compared to those that did not experience TdP, in which the QTc has a fairly steady and predictable course. The bottom two graphs show changes in the right slope of Lead I. This shows a clustering to the top right of the graph in those that experienced TdP suggestive of a Bshallow^T wave, compared to controls, which showed a varied response and no clear underlying pattern.
The Center of gravity (COG), which is derived from mean x and y coordinates of the T wave, is an innovative T wave index that we have demonstrated has potential to account for subtle variations in the T wave [36] . Although the COGx was not selected as our top two correlated variables, there were statistically significant differences between the TdP cases and controls across all ECG leads, where the COGx was longer in all cases (Table 1 -Supplementary File). We postulate that the increase in COG on the x axis in TdP is due to a T wave that is flatter and slightly longer, and thus the COG is able to take into account subtle repolarization variations. This new index has the potential to be a significantly more comprehensive predictor of arrhythmogenic risk. It seems to account for small changes in repolarization in the complete T wave, which other indices fail to do.
Female sex is considered a classic risk factor for TdP [3, 37] . This sex disparity is reflected in our cohort, in which a large majority of the patients who experienced TdP were females (10/13, 77 %). The reasons for this increased risk is unknown but may be due to hormonal factors [38] . Pathophysiology aside, clinicians should be aware of this increased predisposition in women. Hypokalemia and hypomagnesaemia are further risk factors for TdP, but all patients in our study had normal electrolyte values (documented normal potassium and magnesium are required per our protocol for AAD drug loading). Interestingly, all patients who experienced TdP were in sinus rhythm on the preceding ECG. It has been reported that there is increased sensitivity to the QT prolonging effects of class III agents after restoration of sinus rhythm [39] .
Limitations
This study was performed retrospectively on a relatively small number of TdP patients and requires validation in a larger cohort. While we matched on sex and age (within 2 years), there is a potential for confounding by other clinical factors that differ between groups. For example, we did not match on ejection fraction or serum electrolyte levels, which also are independent risk factors for TdP. However there was no calculated statistically significant difference between cases and controls for these variables. Given that the mean time between TdP and the ECG recording of approximately 120 mins, a direct correlation is difficult to completely assess in this context. Extrapolation to a population with paced rhythms is unknown as we excluded them from out cohort. Lastly, this new software program has not been validated in other populations outside of our study.
Conclusion
The combination of a lead V3-derived QTc and a lead I derived T wave right slope discriminated the torsadogenic cases from the non-torsadogenic controls exposed to virtually identical sotalol/dofetilide loads with near 90 % accuracy. Consideration of T wave parameters in addition to the QTc has significant potential to enhance risk stratification in patients. 
Clinical Perspective
Class III antiarrhythmics (sotalol and dofetilide) are common medications used in the management of atrial fibrillation. Initiation of these medications requires serial QTc measurements to help reduce the risk of lethal ventricular arrhythmias. However QTc is an imperfect marker of this risk. Sophisticated T wave analysis could have the potential to predict proarrhythmia, thereby guiding safer patient selection for specific drugs, or prediction of proarrhythmic events to enable drug dose modification or discontinuation. In this study, we aimed to identify T wave morphological changes with the use of a novel T wave analysis program in those patients loaded with class III antiarrhythmics. The main observation is that in addition to QTc, the T wave right slope is correlated strongly with TdP risk. Our findings suggest that measurement of T wave parameters (in particular T wave right slope) in addition to the QTc has significant potential to enhance torsade risk stratification.
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